Oscar Health Inc (NYSE:OSCR) has a beta value of 1.69 and has seen 0.39 million shares traded in the recent trading session. The company, currently valued at $4.19B, closed the recent trade at $17.69 per share which meant it gained $0.13 on the day or 0.74% during that session. The OSCR stock price is -4.86% off its 52-week high price of $18.55 and 73.32% above the 52-week low of $4.72. The 3-month trading volume is 3.12 million shares.
Oscar Health Inc (NYSE:OSCR) trade information
Sporting 0.74% in the green today, the stock has traded in the green over the last five days, when the OSCR stock price touched $17.69 or saw a rise of 2.8%. Year-to-date, Oscar Health Inc shares have moved 93.33%, while the 5-day performance has seen it change 9.33%. Over the past 30 days, the shares of Oscar Health Inc (NYSE:OSCR) have changed 18.96%.
Oscar Health Inc (OSCR) estimates and forecasts
Figures show that Oscar Health Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 264.74% over the past 6 months, with this year growth rate of 81.15%, compared to 14.10% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 250.00% and 357.10% for the next quarter. Revenue growth from the last financial year stood is estimated to be 42.20%.
3 analysts offering their estimates for the company have set an average revenue estimate of $2.01 billion for the current quarter. 3 have an estimated revenue figure of $2.1 billion for the next quarter concluding in Jun 2024. Year-ago sales stood $1.15 billion and $1.52 billion respectively for this quarter and the next, and analysts expect sales will grow by 75.50% for the current quarter and 37.80% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -2.85% over the past 5 years.
OSCR Dividends
Oscar Health Inc is expected to release its next earnings report in May this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
